Genotoxicity of acyl glucuronide metabolites formed from clofibric acid and gemfibrozil: A novel role for phase-II-mediated bioactivation in the hepatocarcinogenicity of the parent aglycones?

Toxicology and Applied Pharmacology

Volumn 147, Issue 2, 1997, Pages 459-464

  Sallustio, Benedetta C ^a,b   Harkin, Louise A ^b   Mann, Maretta C ^b   Krivickas, Sara J ^b   Burcham, Philip C ^b  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFIBRATE; GEMFIBROZIL; GLUCURONIDE;

ARTICLE; DRUG DEGRADATION; DRUG DNA INTERACTION; ESCHERICHIA COLI; GENE MUTATION; GENOTOXICITY; GLYCOSYLATION; LIVER CARCINOGENESIS; LIVER CARCINOMA; LIVER TOXICITY; NONHUMAN; TOXICITY TESTING;

EID: 0031422924     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1997.8322     Document Type: Article

References (27)

1. Ashby J., Brady A., Elcombe C. R., Elliot B. M., Ishamael J., Odum J., Tugwood J. D., Kettle S., Purchase I. F. H. Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Hum. Exp Toxicol. 13:1994;S1-S117.
2. Bailey M. J., Dickinson R. G. Chemical and immunochemical comparison of protein adduct formation of four carboxylate drugs in rat liver and plasma. Chem. Res. Toxicol. 9:1996;659-666.
3. Bucala R., Model P., Cerami A. Modification of DNA by reducing sugars: A possible mechanism for nucleic acid aging and age-related dysfunction in gene expression. Proc. Natl. Acad. Sci. USA. 81:1984;105-109.
4. Bucala R., Model P., Russel M., Cerami A. Modification of DNA by glucose 6-phosphate induces DNA rearrangements in an Escherichia coli plasmid. Proc. Natl. Acad. Sci. USA. 82:1985;8439-8442.
5. Cayen M. N. Metabolism and pharmacokinetics of antihyperlipidaemic agents. Prog. Drug Metab. 7:1983;173-227.
6. Ding A., Ojingwa J. C., McDonagh A. F., Burlingame A. L., Benet L. Z. Evidence for covalent binding of acyl glucuronides to serum albumin via an imine mechanism as revealed by tandem mass spectrometry. Proc. Natl. Acad. Sci. USA. 90:1993;3797-3801.
7. Hargus S. J., Amouzedeh H. R., Pumford N. R., Myers T. G., McCoy S. C., Pohl L. R. Metabolic activation and immunochemical localisation of liver protein adducts of the nonsteroidal anti-inflammatory drug diclofenac. Chem. Res. Toxicol. 7:1994;575-582.
8. 1. Biochem. Biophys. Res. Commun. 237:1997;1-5.
9. Harkin L. A., Butler L. M., Burcham P. C. The role of depurinating lesions in the mutagenicity of alkylperoxyl radicals. Induction of abasic sites in bacteriophage M13mp19. Chem. Res. Toxicol. 10:1997;575-581.
10. Kretz-Rommel A., Boelsterli U. A. Diclofenac covalent protein binding is dependent on acyl glucuronide formation and is inversely related to P450-mediated acute cell injury in cultured rat hepatocytes. Toxicol. Appl. Pharmacol. 120:1993;155-161.
11. Kunkel T. A. Mutational specificity of depurination. Proc. Natl. Acad. Sci. USA. 81:1984;1494-1498.
12. Lee A. T., Cerami A. Elevated glucose 6-phosphate levels are associated with plasmid mutationsin vivo. Proc. Natl. Acad. Sci. USA. 84:1987a;8311-8314.
13. Lee A. T., Cerami A. The formation of reactive intermediate(s) of glucose 6-phosphate and lysine capable of rapidly reacting with DNA. Mutat. Res. 179:1987b;151-158.
14. Monnier V. M. Nonenzymic glycosylation, the Malliard reaction and the aging process. J. Gerontol. Biol. Sci. 45:1990;B105-111.
15. Mulder G. J. Glucuronidation and its role in regulation of biological activity of drugs. Annu. Rev. Pharmacol. Toxicol. 32:1992;25-49.
16. Ojingwa J. C., Spahn-Langguth H., Benet L. Z. Irreversible binding of tolmetin to macromolecules via its glucuronide: Binding to blood constituents, tissue homogenates and subcellular fractionsin vitro. Xenobiotica. 24:1994;495-506.
17. 2. Biochemistry. 34:1995;648-655.
18. Sallustio B. C., Fairchild B. A. Biosynthesis, characterisation and direct high-performance liquid chromatographic analysis of gemfibrozil 1-O. J. Chromatogr. 665:1995;345-353.
19. Sallustio B. C., Fairchild B. A., Pannall P. R. Interaction of human serum albumin with the electrophilic metabolite 1-OD. Drug Metab. Dispos. 25:1997;55-60.
20. Sallustio B. C., Foster D. J. R. Reactivity of gemfibrozil 1-O. Drug Metab. Dispos. 23:1995;892-899.
21. Sallustio B. C., Knights K. M., Roberts B. J., Zacest R. In vivo. Biochem. Pharmacol. 42:1991;1421-1425.
22. Sambrook J., Fritsch E. F., Maniatis T. Molecular Cloning: A Laboratory Manual. 1989;Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
23. Shore L. J., Fenselau C., King A. R., Dickinson R. G. Characterisation and formation of the glutathione conjugate of clofibric acid. Drug Metab. Dispos. 23:1995;119-123.
24. Smith P. C., Wang C. Nonenzymic glycation of albumin by acyl glucuronidesin vitro. Biochem. Pharmacol. 44:1992;1661-1668.
25. Spahn-Langguth H., Benet L. Z. Acyl glucuronides revisited: Is the glucuronidation process a toxification as well as a detoxification mechanism. Drug Metab. Rev. 24:1992;5-48.
26. Van Breemen R. B., Fenselau C. C. Reaction of 1-Op. Drug Metab. Dispos. 14:1986;197-201.
27. Von Daniken A., Lutz W. K., Schlatter C. Lack of covalent binding to rat liver DNA of the hypolipidemic drugs clofibrate and fenofibrate. Toxicol. Lett. 7:1981;311-319.